These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

225 related items for PubMed ID: 9383228

  • 1. High-dose chemotherapy and autologous peripheral blood stem cell transplantation in patients with multiple myeloma and renal insufficiency.
    Ballester OF, Tummala R, Janssen WE, Fields KK, Hiemenz JW, Goldstein SC, Perkins JB, Sullivan DM, Rosen R, Sackstein R, Zorsky P, Saez R, Elfenbein GJ.
    Bone Marrow Transplant; 1997 Oct; 20(8):653-6. PubMed ID: 9383228
    [Abstract] [Full Text] [Related]

  • 2. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
    Arora M, Burns LJ, Barker JN, Miller JS, Defor TE, Olujohungbe AB, Weisdorf DJ.
    Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
    [Abstract] [Full Text] [Related]

  • 3. High-dose melphalan with G-CSF-stimulated whole blood rescue followed by stem cell harvesting and busulphan/cyclophosphamide with autologous stem cell transplantation in multiple myeloma.
    Huijgens PC, Dekker-Van Roessel HM, Jonkhoff AR, Admiraal GC, Zweegman S, Schuurhuis GJ, Ossenkoppele GJ.
    Bone Marrow Transplant; 2001 May; 27(9):925-31. PubMed ID: 11436102
    [Abstract] [Full Text] [Related]

  • 4. High dose chemotherapy followed by autologous haemopoietic stem cell transplant in multiple myeloma.
    Kumar L, Raju GM, Ganessan K, Shawgi S, Menon H, Wadhwa J, Sharma A, Singh R, Kochupillai V.
    Natl Med J India; 2003 May; 16(1):16-21. PubMed ID: 12715951
    [Abstract] [Full Text] [Related]

  • 5. [Complete remission of nephrotic syndrome and improvement of renal function in a patient with light chain deposition disease following high dose chemotherapy with transplantation of autologous haematopoietic stem cells. A case study and review of literature].
    Adam Z, Krejcí M, Pour L, Stepánková S, Cermáková Z, Voska L, Teplan V, Krivanová A, Hájek R, Mayer J.
    Vnitr Lek; 2009 Nov; 55(11):1089-96. PubMed ID: 20017442
    [Abstract] [Full Text] [Related]

  • 6. High-dose chemotherapy with carboplatin, cyclophosphamide and etoposide and autologous transplantation for multiple myeloma relapsing after a previous transplant.
    Mehta J, Tricot G, Jagannath S, Desikan KR, Siegel D, Singhal S, Munshi N, Vesole D, Mattox S, Bracy D, Barlogie B.
    Bone Marrow Transplant; 1997 Jul; 20(2):113-6. PubMed ID: 9244413
    [Abstract] [Full Text] [Related]

  • 7. Phase I-II study of high-dose busulfan and cyclophosphamide followed by autologous peripheral blood stem cell transplantation for hematological malignancies: toxicities and hematopoietic recovery.
    Ballester OF, Agaliotis DP, Hiemenz JW, Janssen WE, Fields KK, Zorksy PE, Goldstein SC, Perkins JB, Elfenbein GJ.
    Bone Marrow Transplant; 1996 Jul; 18(1):9-14. PubMed ID: 8831989
    [Abstract] [Full Text] [Related]

  • 8. High-dose therapy and autologous peripheral blood stem cells transplantation followed by a very low reduced intensity regimen with fludarabine + cyclophosphamide and allograft improve complete remission rate in de novo multiple myeloma patients.
    Martino M, Console G, Irrera G, Praticò G, Stelitano C, Callea V, Morabito F, Quartarone E, Musolino C, Piro E, Brugiatelli M, Iacopino P.
    Am J Hematol; 2006 Dec; 81(12):973-8. PubMed ID: 16888786
    [Abstract] [Full Text] [Related]

  • 9. Modified conditioning regimen busulfan-cyclophosphamide followed by allogeneic stem cell transplantation in patients with multiple myeloma.
    Zhang XH, Huang XJ, Liu KY, Xu LP, Liu DH, Chen H, Chen YH, Wang JZ, Han W, Lu DP.
    Chin Med J (Engl); 2007 Mar 20; 120(6):463-8. PubMed ID: 17439737
    [Abstract] [Full Text] [Related]

  • 10. Early harvest and late transplantation as an effective therapeutic strategy in multiple myeloma.
    Gertz MA, Lacy MQ, Inwards DJ, Chen MG, Pineda AA, Gastineau DA, Greipp PR, Lust JA, Tefferi A, Witzig TE, Kyle RA, Litzow MR.
    Bone Marrow Transplant; 1999 Feb 20; 23(3):221-6. PubMed ID: 10084252
    [Abstract] [Full Text] [Related]

  • 11. Busulfan, cyclophosphamide, and etoposide as conditioning for autologous stem cell transplantation in multiple myeloma.
    Cogle CR, Moreb JS, Leather HL, Finiewicz KJ, Khan SA, Reddy VS, Wingard JR.
    Am J Hematol; 2003 Jul 20; 73(3):169-75. PubMed ID: 12827653
    [Abstract] [Full Text] [Related]

  • 12. A simplified approach to stem cell mobilization in multiple myeloma patients not previously treated with alkylating agents.
    Lerro KA, Medoff E, Wu Y, Seropian SE, Snyder E, Krause D, Cooper DL.
    Bone Marrow Transplant; 2003 Dec 20; 32(12):1113-7. PubMed ID: 14647264
    [Abstract] [Full Text] [Related]

  • 13. Autologous peripheral blood stem cell transplantation as first line treatment of multiple myeloma: an Italian Multicenter Study.
    Tribalto M, Amadori S, Cudillo L, Caravita T, Del Poeta G, Meloni G, Avvisati G, Petrucci MT, Pulsoni A, Leone G, Sica S, Martelli M, Tabilio A, Fioritoni G, Majolino I, Mandelli F.
    Haematologica; 2000 Jan 20; 85(1):52-8. PubMed ID: 10629592
    [Abstract] [Full Text] [Related]

  • 14. Dexamethasone, paclitaxel, etoposide, cyclophosphamide (d-TEC) and G-CSF for stem cell mobilisation in multiple myeloma.
    Bilgrami S, Bona RD, Edwards RL, Li Z, Naqvi B, Shaikh A, Furlong F, Fox J, Clive J, Tutschka PJ.
    Bone Marrow Transplant; 2001 Jul 20; 28(2):137-43. PubMed ID: 11509931
    [Abstract] [Full Text] [Related]

  • 15. High-dose melphalan versus busulfan, cyclophosphamide, and etoposide as preparative regimens for autologous stem cell transplantation in patients with multiple myeloma.
    Benson DM, Elder PJ, Lin TS, Blum W, Penza S, Avalos B, Copelan E, Farag SS.
    Leuk Res; 2007 Aug 20; 31(8):1069-75. PubMed ID: 17070906
    [Abstract] [Full Text] [Related]

  • 16. Autologous stem cell transplantation in multiple myeloma after VAD and EDAP courses: a high incidence of oligoclonal serum Igs post transplantation.
    Hovenga S, de Wolf JT, Guikema JE, Klip H, Smit JW, Smit Sibinga CT, Bos NA, Vellenga E.
    Bone Marrow Transplant; 2000 Apr 20; 25(7):723-8. PubMed ID: 10745257
    [Abstract] [Full Text] [Related]

  • 17. [Autologous transplantation of peripheral hematopoietic cells in a patient with multiple myeloma and renal insufficiency].
    Krejcí M, Doubek M, Adam Z, Hájek R, Vorlícek J, Mayer J.
    Vnitr Lek; 1997 Nov 20; 43(11):756-8. PubMed ID: 9650509
    [Abstract] [Full Text] [Related]

  • 18. A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer.
    Hu WW, Long GD, Stockerl-Goldstein KE, Johnston LJ, Chao NJ, Negrin RS, Blume KG.
    Clin Cancer Res; 1999 Nov 20; 5(11):3411-8. PubMed ID: 10589752
    [Abstract] [Full Text] [Related]

  • 19. Autologous stem cell transplantation in multiple myeloma: outcome in patients with renal failure.
    Knudsen LM, Nielsen B, Gimsing P, Geisler C.
    Eur J Haematol; 2005 Jul 20; 75(1):27-33. PubMed ID: 15946307
    [Abstract] [Full Text] [Related]

  • 20. Thalidomide-dexamethasone as induction therapy before autologous stem cell transplantation in patients with newly diagnosed multiple myeloma and renal insufficiency.
    Tosi P, Zamagni E, Tacchetti P, Ceccolini M, Perrone G, Brioli A, Pallotti MC, Pantani L, Petrucci A, Baccarani M, Cavo M.
    Biol Blood Marrow Transplant; 2010 Aug 20; 16(8):1115-21. PubMed ID: 20197100
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.